What is the Zacks rating for CRISPR stock? (2024)

What is the Zacks rating for CRISPR stock?

Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

Is Crispr a buy sell or hold?

Crispr stock is rated as a Moderate Buy, according to analysts, with 10 Buys, five Holds, and two Sells assigned in the past three months. The average CRSP stock price target is $80.47, with a high forecast of $112 and a low forecast of $30.

What is the buy rating for CRSP?

Crispr Therapeutics AG has 27.91% upside potential, based on the analysts' average price target. Is CRSP a Buy, Sell or Hold? Crispr Therapeutics AG has a conensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 2 sell ratings.

What is the future of CRSP stock?

Based on short-term price targets offered by 22 analysts, the average price target for CRISPR Therapeutics AG comes to $88.00. The forecasts range from a low of $30.00 to a high of $199.00. The average price target represents an increase of 58.39% from the last closing price of $55.56.

What is the CRISPR stock price forecast for 12 months?

CRISPR Therapeutics AG Stock Forecast

The 17 analysts with 12-month price forecasts for CRSP stock have an average target of 79.76, with a low estimate of 30 and a high estimate of 160. The average target predicts an increase of 37.61% from the current stock price of 57.96.

What Crispr company did Bill Gates invest in?

Our genius IT CEO Bill Gates and his friends decided to put their hands to “The Genesis Engine”, the new favorite of DNA editing in the lab, CRISPR. They poured $120 Million, as the title of this article said, into this project for a company named Editas Medicine, which lead the CRISPR to the world.

What will CRSP stock be worth in 2025?

CRISPR Therapeutics AG Stock Prediction 2025

The CRISPR Therapeutics AG stock prediction for 2025 is currently $ 75.22, assuming that CRISPR Therapeutics AG shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 34.02% increase in the CRSP stock price.

Why is CRSP price negative?

Sometimes you see negative stock prices in CRSP. This means that there was no closing price available for that period. Instead, the bid/ask average was used. To distinguish the bid/ask averages from actual closing prices, CRSP puts a leading dash in front of the price when the bid/ask average was used.

What is the stock price forecast for Crispr in 2024?

CRISPR Therapeutics stock price stood at $56.16

According to the latest long-term forecast, CRISPR Therapeutics price will hit $80 by the end of 2024 and then $110 by the end of 2025. CRISPR Therapeutics will rise to $125 within the year of 2027, $150 in 2028 and $200 in 2033.

What is the delisting return of a CRSP?

Delisting Return

If there is no opportunity to trade a stock after delisting before it is declared worthless, the value after delisting is zero. Delisting Returns are calculated similarly to total returns except that the value after delisting is used as the current price.

Where will CRISPR be in 5 years?

In other words, 2024 should be a busy year for the company. The work it does throughout the next 12 months should help it lay a foundation for future major regulatory success beyond Casgevy. In the next five years, expect the company to earn approval for at least one more CRISPR-based gene editing treatment.

Is CRSP profitable?

Full-Year Results. For 2023, CRISPR generated total revenues of $371.2 million, reflecting a substantial increase over the previous year's revenues of $1.2 million. Most of the 2023 total revenues comprised collaboration revenues from Vertex.

Does BlackRock own CRISPR?

Institutional Ownership and Shareholders

Rowe Price Investment Management, Inc., ANWPX - NEW PERSPECTIVE FUND Class A, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., BlackRock Inc., Fmr Llc, and State Street Corp .

Where will CRISPR be in 10 years?

Over the next 10 years, we expect the biomedical applications of CRISPR to accelerate: A second wave of in vivo clinical trials including larger indications. Innovations enabling delivery of CRISPR to a greater variety of tissue.

Does CRSP pay dividends?

There are no CRISPR Therapeutics AG dividends.

Who owns CRISPR Therapeutics?

Emmanuelle Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun Foy. She is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany.

What company has the best CRISPR technology?

What company is working on CRISPR?

Located in Berkeley, California, Caribou Biosciences develops next-generation genome-edited cell therapeutics using its innovative CRISPR platform aimed at improving the lives of patients suffering from life-threatening diseases.

What biotech does Bill Gates own?

BioNTech accounts for 17.5% of the Bill and Melinda Gates Foundation portfolio, which owns almost 148,000 shares valued at $15.7 million.

What is the dividend yield for CRSP?

The current dividend yield for CRISPR Therapeutics AG as of April 17, 2024 is 0.00%.

How many shares of CRSP does Ark own?

Aside from Steven Boyd's Armistice Capital, CRISPR Therapeutics AG (NASDAQ:CRSP)'s biggest hedge fund investor is Catherine D. Wood's ARK Investment Management as it owns 7.1 million shares that are worth $325 million.

How much cash does CRSP have?

Cash on Hand as of December 2023 : $1.69 B.

Is Crispr stock undervalued?

We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very undervalued, currently trading about 53% below our fair value estimate.

What are the problems with CRISPR Therapeutics?

However, the in vivo use of the CRISPR/Cas9 system has faced many challenges such as the occurrence of off-targeting modifications, the possibility of causing autoimmune diseases, the identification of a proper delivery technique, and, lastly, ethical concerns.

What are the potential downsides of Crispr?

Off-target effects are a major concern for CRISPR-Cas9 experiments, and they can be challenging to predict. Efforts have been made to improve in silico off-target prediction tools as well as to reduce off-target effects by improving Cas9 nucleases [11,12].